 |
 |
 |
 |

September 2008 Cover
|
 |
In a separate analysis of data published in the same issue of the Journal of Infectious Diseases, findings from other recent studies regarding the benefits of early anti-HIV were reaffirmed. Among a subset of trial participants who were either antiretroviral naive or had not received therapy in the preceding six months, those who initiated treatment with a CD4 cell count greater than 350 were found to be significantly less likely to develop an opportunistic infection, develop a serious non-AIDS-defining event, or die than patients who initiated treatment when their CD4 cell count dropped below 250.
from TheBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
 |
|
 |